Ivarmacitinib

Autoimmune inflammatory diseases are thought to arise from a complex interplay of genetics, microbiota, and environmental factors that ultimately lead to dysregulated T- and B-cell activity against the host. Therapeutic interventions are therefore aimed at suppressing T-cell activity and/or blocking cytokine activity. A therapeutic target of particular interest is the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway, the dysregulation of which has been implicated in a variety of immune disorders. Put simply, the JAK-STAT pathway plays a significant role in the transduction of signals from cell membrane receptors to the nucleus, and is essential for the transcription of a range of cytokines and growth factors, including those responsible for orchestrating innate and adaptive immune responses. The JAK family of non-receptor tyrosine kinases includes JAK1, JAK2, JAK3, and TYK2, each of which comprise several distinct domains and serve distinct functions.

Ivarmacitinib is a highly selective inhibitor of JAK1 - which modulates IL-4, IL-5, IL-13, and IFN-γ, amongst other cytokines - while sparing inhibition of JAK2 in order to decrease the risk of adverse effects like anemia and neutropenia. By inhibiting this pathway, ivarmacitinib may help to prevent the immune dysregulation responsible for a number of inflammatory conditions, including atopic dermatitis and rheumatologic diseases (e.g. rheumatoid arthritis).